Triple Agonists Explained: The Future of Weight Loss Treatment

Introduction#

The evolution of anti-obesity pharmacotherapy has followed a clear trajectory: from single to dual to triple receptor agonists, with each generation producing greater weight loss. The latest clinical data from retatrutide's Phase 3 TRIUMPH program confirmed what the field had hypothesized -- targeting three metabolic hormone receptors simultaneously produces the highest weight loss ever observed in clinical trials.

This review examines the science behind triple (and quadruple) receptor agonists, why adding glucagon receptor agonism to the GLP-1 backbone matters, and what the clinical data reveal about this emerging drug class.

Important: All triple and quadruple agonists discussed are investigational. None are FDA-approved.

The Evolution: From Single to Triple Agonism#

Generation 1: GLP-1 Monoagonists#

The first generation targeted only the GLP-1 receptor:

• Semaglutide (Wegovy): 14.9% weight loss at 68 weeks
• Mechanism: Appetite suppression, delayed gastric emptying, improved insulin sensitivity

Generation 2: Dual Agonists#

Adding a second receptor target improved efficacy:

• Tirzepatide (GLP-1 + GIP): 20.9% weight loss at 72 weeks
• Survodutide (GLP-1 + glucagon): 18.7% at 46 weeks
• CagriSema (GLP-1 + amylin): 22.7% at 68 weeks

Generation 3: Triple Agonists#

Adding a third receptor pushed weight loss further:

• Retatrutide (GLP-1 + GIP + glucagon): 28.7% at 68 weeks

Generation 4: Quadruple Agonists#

The latest frontier adds a fourth receptor:

• Bioglutide/NA-931 (GLP-1 + GIP + glucagon + IGF-1): 13.8% at 13 weeks (Phase 2)

Why Glucagon Matters#

The addition of glucagon receptor agonism to the GLP-1 backbone is the key innovation distinguishing triple agonists from dual GLP-1/GIP agonists like tirzepatide. Glucagon contributes to weight loss through mechanisms distinct from GLP-1:

Energy Expenditure#

Glucagon increases resting energy expenditure by stimulating hepatic thermogenesis and brown adipose tissue activation. While GLP-1 primarily reduces energy intake (appetite suppression), glucagon increases energy output, attacking the energy balance equation from both sides simultaneously.

Hepatic Fat Metabolism#

Glucagon promotes hepatic beta-oxidation of fatty acids and reduces hepatic lipogenesis. This is why glucagon-containing agonists (survodutide, retatrutide) show particular promise for MASH/MASLD, where liver fat accumulation is the core pathology.

Amino Acid Metabolism#

Glucagon stimulates amino acid catabolism and ureagenesis. This may have implications for lean mass dynamics, though the clinical impact is complex and dose-dependent.

Glycogenolysis#

Glucagon promotes glycogen breakdown, which could theoretically raise blood glucose. However, in the context of dual or triple agonists, the concurrent GLP-1 agonism (which promotes insulin secretion and suppresses glucagon) counterbalances this effect, maintaining glycemic control.

Retatrutide: The Triple Agonist Leader#

Mechanism#

Retatrutide is a single peptide molecule that activates three receptors:

• GLP-1 receptor: Appetite suppression, insulin secretion, delayed gastric emptying
• GIP receptor: Insulin potentiation, possible adipose tissue effects
• Glucagon receptor: Increased energy expenditure, hepatic fat oxidation

The peptide uses a C20 fatty diacid to enable albumin binding and a ~5-day half-life for weekly dosing.

Phase 3 TRIUMPH-4 Results#

The TRIUMPH-4 trial enrolled participants with obesity and knee osteoarthritis:

Key secondary outcomes at 12 mg:

• Average weight loss of 71.2 lbs (32.3 kg)
• Systolic blood pressure reduced by 14.0 mmHg
• Significant improvements in non-HDL cholesterol, hs-CRP, and triglycerides
• WOMAC knee pain reduced by 75.8% (4.5 points)
• More than 1 in 8 patients were completely free of knee pain

Why 28.7% Is Remarkable#

To put retatrutide's result in context:

The incremental benefit of adding glucagon agonism (retatrutide vs tirzepatide) appears to be approximately 7-8 percentage points of additional weight loss, comparable to the benefit of adding GIP agonism to GLP-1 alone (tirzepatide vs semaglutide, ~6 percentage points).

Phase 3 Program#

Seven additional Phase 3 TRIUMPH readouts are expected in 2026, including studies evaluating maintenance dosing strategies. The full program will generate data across obesity, T2D, obstructive sleep apnea, and osteoarthritis.

The Glucagon Partners: Survodutide and Pemvidutide#

While retatrutide combines glucagon with GLP-1 and GIP, two other drugs pair glucagon specifically with GLP-1, helping isolate glucagon's contribution:

Survodutide (Boehringer Ingelheim)#

Mechanism: Dual GLP-1/glucagon agonist Phase 2: 18.7% weight loss at 46 weeks Phase 3: SYNCHRONIZE program, results expected 2026 Breakthrough therapy designation: For MASH

Survodutide's 18.7% result demonstrates that GLP-1 + glucagon alone produces weight loss exceeding GLP-1 monoagonism (~15%) but below retatrutide's triple agonism (~29%). The glucagon component contributes approximately 3-4 percentage points of additional weight loss beyond GLP-1 alone.

Pemvidutide (Altimmune)#

Mechanism: Dual GLP-1/glucagon agonist Phase 2 MOMENTUM: 15.6% weight loss at 48 weeks Key differentiator: Class-leading lean mass preservation

Pemvidutide's most notable feature is body composition: only 21.9% of weight lost was lean mass, compared to the typical 25-40% with GLP-1 agonists alone. This suggests that glucagon's thermogenic effects may preferentially target fat mass while preserving muscle, a critical advantage for long-term metabolic health.

Bioglutide (NA-931): The Quadruple Agonist#

A New Paradigm#

Bioglutide (NA-931) represents the next leap in multi-receptor agonism. Developed by Biomed Industries, it is the first oral small molecule that simultaneously activates four metabolic hormone receptors:

1. GLP-1 receptor: Appetite suppression, glycemic control
2. GIP receptor: Insulin potentiation
3. Glucagon receptor: Energy expenditure, liver fat reduction
4. IGF-1 receptor: Growth signaling, anabolic effects

Why IGF-1?#

The addition of IGF-1 receptor agonism is the most novel aspect of bioglutide. IGF-1 signaling promotes:

• Muscle protein synthesis and preservation of lean mass
• Bone mineral density maintenance
• Cellular repair and regeneration

In theory, activating IGF-1 alongside the weight-loss-inducing GLP-1, GIP, and glucagon pathways could preserve or even increase lean mass during weight loss, addressing one of the most significant limitations of current anti-obesity therapies.

Phase 2 Results#

A 13-week multiple ascending dose study enrolled 125 participants:

Additional findings:

• Up to 72% of treated subjects achieved 12% or greater weight loss at 13 weeks
• No muscle loss was observed
• TEAEs were insignificant or mild
• Drug absorption was unaffected by food (no fasting required)
• Oral daily dosing

Caveats#

While the Phase 2 data are impressive, several caveats apply:

• Small sample size (125 participants)
• Short duration (13 weeks)
• Limited peer-reviewed publication
• The company (Biomed Industries) is a smaller biotech without the resources of Lilly or Novo Nordisk
• Phase 3 has been announced but details are limited

Comparing Multi-Receptor Approaches#

The Glucagon Safety Question#

Adding glucagon agonism raises specific safety considerations:

Hyperglycemia Risk#

Glucagon's primary physiological role is to raise blood glucose. In the context of triple agonists, GLP-1-mediated insulin secretion counterbalances this effect. In TRIUMPH-4, retatrutide did not produce clinically significant hyperglycemia. However, the balance between glucagon's hyperglycemic potential and GLP-1's glucose-lowering effect may be critical in patients with type 2 diabetes.

Heart Rate#

GLP-1 agonists typically increase heart rate by 2-4 bpm. Glucagon can also increase heart rate. Whether triple agonists produce additive heart rate effects requires monitoring in Phase 3 studies.

GI Tolerability#

Triple agonism produces higher GI side effect rates than dual agonism. In retatrutide Phase 2 data, nausea (38-43%), diarrhea (33-35%), and vomiting (20-21%) were all higher than with tirzepatide or semaglutide. Whether this is a dose-dependent effect that can be mitigated with optimized titration is being evaluated in the TRIUMPH program.

Hepatic Effects#

Glucagon stimulates amino acid metabolism and ketogenesis, which could theoretically stress the liver. However, the net effect appears beneficial: survodutide has breakthrough therapy designation for MASH precisely because glucagon agonism reduces hepatic steatosis.

What the Data Tell Us#

The Receptor Hierarchy#

The clinical data suggest an approximate hierarchy of weight loss contribution:

1. GLP-1 agonism alone: ~15% weight loss (semaglutide)
2. Adding GIP agonism: +5-6 pp (tirzepatide ~21%)
3. Adding glucagon agonism: +3-4 pp (survodutide ~19%) or +7-8 pp when combined with GIP (retatrutide ~29%)
4. Adding IGF-1 agonism: Under investigation (bioglutide early data)

The combination of all three incretin-related pathways (GLP-1 + GIP + glucagon) appears to produce a synergistic rather than merely additive effect on weight loss.

The Body Composition Question#

Triple agonists may preserve lean mass better than GLP-1 monoagonists. Pemvidutide's 78.1% fat mass ratio is significantly better than the typical 60-75% observed with GLP-1 alone. Retatrutide's glucagon component and bioglutide's IGF-1 component may also contribute to lean mass preservation, though definitive body composition data are pending.

What to Watch in 2026#

1. Retatrutide TRIUMPH readouts -- Seven more Phase 3 results expected, which will define the drug's clinical profile across multiple indications
2. Survodutide SYNCHRONIZE results -- Phase 3 data will establish whether GLP-1/glucagon dual agonism achieves >20% weight loss at longer treatment durations
3. Bioglutide Phase 3 initiation -- Advancement of the first quadruple agonist into late-stage development
4. Body composition data -- Lean mass preservation may become as important as total weight loss in differentiating next-generation agents

Conclusion#

Triple agonists represent the current frontier of anti-obesity pharmacotherapy. Retatrutide's 28.7% weight loss in Phase 3 confirms that targeting GLP-1, GIP, and glucagon receptors simultaneously produces weight loss approaching bariatric surgery levels. The emergence of quadruple agonists like bioglutide, which add IGF-1 signaling to address lean mass preservation, suggests the field is far from reaching its ceiling.

The key question going forward is not whether multi-receptor agonists are more effective -- they clearly are -- but how to optimize the risk-benefit ratio: maximizing weight loss and metabolic improvement while maintaining tolerability and safety.

This article is for educational and informational purposes only. It does not constitute medical advice.

References#

Related Peptide Profiles#

Learn more about the peptides discussed in this article:

• Retatrutide Overview and Research Guide
• Retatrutide Dosing Protocols
• Retatrutide Side Effects and Safety
• Survodutide Overview and Research Guide
• Survodutide Dosing Protocols
• Survodutide Side Effects and Safety
• Pemvidutide Overview and Research Guide
• Pemvidutide Dosing Protocols
• Pemvidutide Side Effects and Safety
• Bioglutide Overview and Research Guide
• Bioglutide Dosing Protocols
• Bioglutide Side Effects and Safety
• Semaglutide Overview and Research Guide
• Semaglutide Dosing Protocols
• Semaglutide Side Effects and Safety